

VLCAD Antibody (C-Term, near)
Peptide-affinity purified goat antibody
Catalog # AF3126a**Specification**

VLCAD Antibody (C-Term, near) - Product Information

Application	WB
Primary Accession	P49748
Other Accession	NP_000009.1 , NP_001029031.1 , 37
Reactivity	Human
Predicted	Dog, Cow
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	70390

VLCAD Antibody (C-Term, near) - Additional Information**Gene ID** 37**Other Names**

Very long-chain specific acyl-CoA dehydrogenase, mitochondrial, VLCAD, 1.3.8.9, ACADVL, VLCAD

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

VLCAD Antibody (C-Term, near) is for research use only and not for use in diagnostic or therapeutic procedures.

VLCAD Antibody (C-Term, near) - Protein Information**Name** ACADVL ([HGNC:92](#))**Function**

Very long-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed:7668252, PubMed:9461620, PubMed:18227065, PubMed:9839948, PubMed:9839948).

href="http://www.uniprot.org/citations/9599005" target="_blank">9599005). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl- CoA (PubMed:7668252, PubMed:9461620, PubMed:18227065, PubMed:9839948). Among the different mitochondrial acyl-CoA dehydrogenases, very long- chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 12 to 24 carbons long primary chains (PubMed:21237683, PubMed:9839948).

Cellular Location

Mitochondrion inner membrane; Peripheral membrane protein

Tissue Location


Predominantly expressed in heart and skeletal muscle (at protein level). Also detected in kidney and liver (at protein level).

VLCAD Antibody (C-Term, near) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

VLCAD Antibody (C-Term, near) - Images



AF3126a (1 µg/ml) staining of Human Heart lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

VLCAD Antibody (C-Term, near) - Background

This antibody is expected to recognize both reported isoforms (NP_000009.1; NP_001029031.1).

VLCAD Antibody (C-Term, near) - References

Genetic

basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, Andresen BS, Yamaguchi S, Mandel H, Fukao T, Ruiter JP, Wanders RJ, McAndrew R, Kim JJ, Bastin J. Am J Hum Genet. 2007 Dec;81(6):1133-43. PMID: 17999356